Market Overview
The Global Viral Vector and Plasmid DNA Manufacturing Market are expected to grow at a high CAGR of 18.8% during the forecasting period (2021-2028).
(YourDigitalWall Editorial):- Anchorage, Alaska Nov 10, 2021 (Issuewire.com) – Market Overview
The Global Viral Vector and Plasmid DNA Manufacturing Market are expected to grow at a high CAGR of 18.8% during the forecasting period (2021-2028).
The viral vector is referred to as the tool for delivering genetic material into cells. The modified viral vector is used as viral vector in gene therapy. Plasmid DNA is a bacterial smaller, circular, and extrachromosomal DNA used in different molecular genetic research such as gene therapy, gene transfer, and recombinant DNA technology due to its self-replication property. A gene of interest is transferred into the target cell for studying the function or expression of a gene.
Download free sample: https://www.datamintelligence.com/download-sample/viral-vector-and-plasmid-dna-manufacturing-market
Market Dynamics:
The market is driven by the increasing demand for viral vectors and plasmid DNA manufacturing for developing DNA vaccines, gene therapy, immunotherapy, and others. There are growing viral vectors & plasmid DNA due to their advantages such as high transfection efficiency, effective gene delivery, and stable gene expression. There is an increase in the number of clinical studies examining the viral vectors’ efficacy and safety and plasmid DNA.
There is an increase in the contract manufacturing business launch for viral vectors and plasmid DNA manufacturing. For instance, in December 2019, Helixmith Co., Ltd. and Genopis had launched the contract manufacturing business for plasmid DNA production. The company would establish additional smaller-scale reactors (60-300 L, 6-30 L) with feasibility runs and start a small-volume production service. Genopis is equipped with the right technologies and quality systems.
Several companies are entering into a collaboration with several organizations to manufacture viral vectors and plasmid DNA. For instance, in June 2020, Oxford Biomedica plc had entered into a collaboration agreement with the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organization established to provide the UK’s first strategic vaccine development and advanced manufacturing capability. This five-year agreement would involve the organizations working collaboratively to enable the manufacture of viral vector-based vaccines, contributing to a rapid increase in the United Kingdom’s domestic capacity for this specialized vaccine manufacturing field. Under the terms of the agreement, VMIC would provide manufacturing equipment for Oxford Biomedica to equip two new GMP manufacturing suites within Oxford Biomedica’s new 7,800 m2 commercial manufacturing center, Oxbox, located in Oxford, United Kingdom.
Segment Analysis
By Product Type
- Plasmid DNA
- Viral Vector
- Non-Viral Vector
By Application
- Cancer
- Genetic Disorder
- Infectious Disease
- Other Diseases
Geographical Presentation
By region, the global viral vector and plasmid DNA manufacturing market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global viral vector and plasmid DNA manufacturing market and is expected to grow at the highest CAGR during the forecasted period due to the increasing number of clinical studies for evaluating the use of the viral vector and plasmid DNA for the treatment of the genetic disorders, cancer, and infectious diseases. The increase in the approval of advanced cell therapies shall stimulate market growth. There is growing research and development activities of gene therapies. Several companies, institutes, associations, and foundations raise the investment and funding to develop gene therapies. The growing initiatives by the Food and Drug Administration (FDA) for improving the regulatory support for cell and gene therapy shall boost the demand for viral vector and plasmid DNA manufacturing.
The Asia Pacific is expected to witness positive market growth due to the growing clinical transformation and industrialization of advanced therapies medicinal products, including gene therapy manufacturing. There is a presence of several companies manufacturing the viral vector and plasmid DNA. Contract manufacturers are providing several services for viral vector and plasmid DNA manufacturing. There is growing adoption of advanced technologies for manufacturing viral vectors and plasmid DNA.
Competitive Analysis
The global viral vector and plasmid DNA manufacturing market is highly competitive with several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Brammer Bio, Cobra Biologics, Cell and Gene Therapy Catapult, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, SIRION Biotech, Merck KGaA Inc., Thermo Fisher Scientific, and Uniqure NV are the leading market players with significant market share.
The major players enter into collaborations, acquisitions, mergers, and licensing activities to increase their market presence. For instance, in August 2019, FUJIFILM Corporation had acquired the Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark, from Biogen. The Hillerød Manufacturing site would be the fourth biopharmaceutical manufacturing site of FUJIFILM Diosynth Biotechnologies, a Fujifilm subsidiary, and a leading Contract Development and Manufacturing Organization (CDMO) with expertise in the development and manufacture of biologics and advanced therapies.
In March 2019, Merck had entered into the non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on a plasmid and viral vector manufacturing. The manufacturing of high-quality plasmids and viral vectors would help in the commercialization of cell and gene therapy. This collaboration would help the company accelerate the industrialization and commercialization of cell and gene therapy in China. Merck would provide GenScript with comprehensive products, training, consulting services covering process design, facility concept design, and quality management system set-up from lab development to large-scale GMP manufacturing.
In December 2017, MilliporeSigma had entered into the commercial supply agreement to manufacture viral vectors for bluebird bio, Inc., of Cambridge, Massachusetts, for its use in potentially transformative gene therapies. MilliporeSigma would manufacture lentiviral vectors for bluebird bio’s drug products developed to treat various rare genetic diseases under the agreement’s terms. This contract builds upon MilliporeSigma’s deep experience producing viral vectors for gene therapy from clinical to commercial scale.
View full report:https://www.datamintelligence.com/research-report/viral-vector-and-plasmid-dna-manufacturing-market
Related reports:
Media Contact
DataM Intelligence
+18774414866
India
